menu search

VYNT / Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery

Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery
Vyant Bio (NASDAQ:VYNT) Inc ended its 2021 financial year with a beefed-up cash balance of $20.6 million to help the biotechnology company pursue its development of drugs for complex neurodevelopmental and neurodegenerative disorders. The company is focused primarily on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome, CDKL5 Deficiency Disorder, and familial Parkinson's Disease. Read More
Posted: Mar 30 2022, 12:06
Author Name: Proactive Investors
Views: 110753

VYNT News  

Vyant Bio to pursue listing on OTC Pink Open Market

By Proactive Investors
May 12, 2023

Vyant Bio to pursue listing on OTC Pink Open Market

Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist  more_horizontal

Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives

By Proactive Investors
February 3, 2023

Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives

Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agree more_horizontal

Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value

By Proactive Investors
January 4, 2023

Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value

Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on more_horizontal

Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 17, 2022

Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript

Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Office more_horizontal

Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show

By Proactive Investors
November 15, 2022

Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show

Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at leas more_horizontal

Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million

By Proactive Investors
November 3, 2022

Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million

Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, a more_horizontal

Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year

By Proactive Investors
August 23, 2022

Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year

Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early more_horizontal

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 22, 2022

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript

Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Ch more_horizontal


Search within

Pages Search Results: